معرفی
Cathy Xie is a Research Fellow at the Australian Translational Medicinal Chemistry Facility (ATMCF), affiliated with the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University. Her research is centered on drug discovery, medicinal chemistry, and translational development, with a focus on inflammatory diseases and challenging enzyme targets.
Education:
- PhD in Medicinal Chemistry, Monash University (2016–2020)
- Bachelor of Science in Pharmaceutical Sciences, China Pharmaceutical University (2012–2016)
Her research interests lie at the intersection of medicinal chemistry and immunology, particularly in the development of inhibitors targeting Glutathione Transferase Omega-1 (GSTO1) for treating inflammatory conditions. Her work combines synthetic chemistry, enzyme kinetics, and molecular pharmacology to advance therapeutic candidates.
The analysis of her recent publications reveals a strong thematic focus on GSTO1 inhibition, inflammasome regulation, and anthelmintic drug development. Her studies span from hit discovery and SAR optimization to mechanistic investigations in cellular and animal models, reflecting a multidisciplinary approach to drug discovery.
Scientific Awards and Recognitions:
- No specific awards are mentioned in the provided text.
While there is no explicit mention of grants or student supervision, her collaborative publications indicate active participation in research teams. Her work has been highlighted on multiple platforms including X (formerly Twitter) and Mendeley, and one of her outputs is referenced in a patent, underscoring its translational potential.
Labs and Research Teams:
She is affiliated with the Australian Translational Medicinal Chemistry Facility (ATMCF) at Monash University, a hub for advancing drug candidates from discovery to preclinical development. Her work is highly collaborative, involving teams across immunology, parasitology, and structural biology.
